« Previous AbstractElevated lead exposure in Australian hunting dogs during a deer hunting season    Next AbstractExpression of two barley proteinase inhibitors in tomato promotes endogenous defensive response and enhances resistance to Tuta absoluta »

Clin Appl Thromb Hemost

Title:		"Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management"
Author(s):		Hamza MS; Mousa SA;
Address:		"Clinical Pharmacy Practice Department, Faculty of Pharmacy, 120633The British University in Egypt, Cairo, Egypt. The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, 120633The British University in Egypt, Cairo, Egypt. The Pharmaceutical Research Institute, 1091Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA"
Journal Title:		Clin Appl Thromb Hemost
Year:		2020
Volume:		26
Issue:
Page Number:		1.07603E+15 -
DOI:		10.1177/1076029620954282
ISSN/ISBN:		1938-2723 (Electronic) 1076-0296 (Print) 1076-0296 (Linking)
Abstract:		"Venous thromboembolism (VTE) is a major health problem in patients with cancer. Cancer augments thrombosis and causes cancer-associated thrombosis (CAT) and vice versa thrombosis amplifies cancer progression, termed thrombosis-associated cancer (TAC). Risk factors that lead to CAT and TAC include cancer type, chemotherapy, radiotherapy, hormonal therapy, anti-angiogenesis therapy, surgery, or supportive therapy with hematopoietic growth factors. There are some other factors that have an effect on CAT and TAC such as tissue factor, neutrophil extracellular traps (NETs) released in response to cancer, cancer procoagulant, and cytokines. Oncogenes, estrogen hormone, and thyroid hormone with its integrin alphavbeta3 receptor promote angiogenesis. Lastly, patient-related factors can play a role in development of thrombosis in cancer. Low-molecular-weight heparin and direct oral anticoagulants (DOACs) are used in VTE prophylaxis and treatment rather than vitamin K antagonist. Now, there are new directions for potential management of VTE in patients with cancer such as euthyroid, blockade of thyroid hormone receptor on integrin alphavbeta3, sulfated non-anticoagulant heparin, inhibition of NETs and stratifying low and high-risk patients with significant bleeding problems with DOACs"
Keywords:		Humans Neoplasms/*complications Risk Factors Thrombosis/*etiology/pathology/*therapy angiogenesis anticoagulants cancer coagulation heparins inflammation integrin alphavbeta3 non-anticoagulant heparin oral anticoagulant thrombosis thyroid hormone;
Notes:		"MedlineHamza, Marwa S Mousa, Shaker A eng 2020/09/03 Clin Appl Thromb Hemost. 2020 Jan-Dec; 26:1076029620954282. doi: 10.1177/1076029620954282"